The global lung cancer drugs market size is expected to grow from $28.45 billion in 2021 to $32.98 billion in 2022 at a compound annual growth rate (CAGR) of 15.9%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global lung cancer drug market is expected to reach $56.00 billion in 2026 at a CAGR of 14.2%.
What is the Global Lung Cancer Drugs Market?
The lung cancer drugs market consists of sales of lung cancer drugs. Lung cancer is a type of cancer that decreases the ability of lungs to supply oxygen to the bloodstream because of uncontrolled growth of tissues in the lung. Some of the possible treatments for lung cancer include surgery, chemotherapy, radiation therapy and targeted therapy. On the basis of the size of the tumor cells, lung cancer is broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
Get a Sample of the global lung cancer drugs market report
https://www.thebusinessresearchcompany.com/sample.aspx?id=2567&type=smp
What drives the Global Lung Cancer Drugs Market?
The rising prevalence rate of lung cancer is a major driver for the lung cancer market. This is mainly because an increase in prevalence and incidence rate of lung cancer cases propels the need for drugs that enable efficient and fast treatment of the disease. It also drives the industry to maintain a strong pipeline of drugs. According to the World Health Organization report, cancer led to around 10 million deaths in 2020, out of which, lung cancer was responsible for the largest number of deaths (1.80 million deaths).
Get the full global lung cancer drugs industry report here
https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report
Global Lung Cancer Drugs Market Segments
The global lung cancer drugs market is segmented:
By Disease Type: Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC)
By End-User: Hospitals, Clinics, Others
By Drug: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Others
By Geography: The regions covered in the lung cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Lung Cancer Drugs Global Market Report 2022provides market size and growth forecasts for the global lung cancer drugs market, global lung cancer drugs market share, lung cancer drugs market segments and geographies, lung cancer drugs market competitive landscape including leading competitors’ revenues, profiles and market shares. The lung cancer drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Global Lung Cancer Drugs Industry Players include Bristol-Myers Squibb Company, Merck & Co., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., GlaxoSmithKline, Vertiv Co., Sanofi-Aventis, Sun Pharmaceuticals Industries and Celgene Corporation. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.
